Highlights
1 patent
About
Immune Checkpoint Inhibitors
NTB Pharma seeks to develop novel targets for immuno-oncology and cancer immunotherapy utilizing the SLAM family receptors. NTB Pharma hypothesizes that SLAMF6, a highly potent agonistic receptor on immune cells, is a natural candidate for anti-melanoma immunotherapy. Its uniqueness may lie in a dual action on lymphocytes and myeloid-derived suppressor cells, augmenting T-cell function and reversing the deleterious effect of the tumor environment. NTB Pharma was established based on a technology developed in the laboratory of Prof. Lotem at Hadassah Medical Center, Jerusalem.
Identity
| Name | NTB Pharma |
|---|---|
| Slug | ntb-pharma |
| Type / kind | startup |
| Crunchbase ID | nt-pharma-group |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwJXhsY0LDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Sep 2017 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | 8 Sderot Churchill, Jerusalem |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biotechnologydiagnosticsregenerative-medicinemedical-technologiescancercancer-therapycell-therapy
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}